Zura Bio’s (ZURA) “Neutral” Rating Reaffirmed at HC Wainwright

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 1.63% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Friday. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th.

Zura Bio Trading Up 0.6 %

Shares of Zura Bio stock opened at $4.92 on Monday. The stock has a 50 day moving average price of $3.92 and a 200-day moving average price of $3.96. Zura Bio has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Sell-side analysts expect that Zura Bio will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 15.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zura Bio

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in Zura Bio during the second quarter worth approximately $43,000. Renaissance Technologies LLC increased its stake in shares of Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the period. SG Americas Securities LLC acquired a new position in Zura Bio during the third quarter worth $62,000. Forefront Analytics LLC boosted its stake in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after acquiring an additional 7,531 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after acquiring an additional 6,412 shares during the period. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.